THE ROLE OF MELATONIN DEFICIENCY IN THE GENESIS OF ARTERIAL HYPERTENSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Abstract
The study analyzed the prevalence of hypertension and impaired melatonin-forming function of the epiphysis in patients with stage 5 chronic kidney disease treated with hemodialysis. The relationship between epiphysis dysfunction and hypertension has been identified. 130 persons (50% of men) undergoing permanent hemodialysis treatment were examined. Controls were 20 healthy individuals. The determination of daytime and nighttime levels of melatonin in saliva and clinical and laboratory studies. As a result of the study it was found that for patients with stage 5 chronic kidney disease undergoing treatment, there is a frequent violation of melatonin-forming function of the pineal gland (84.6%) and hypertension (78%). In hemodialysis patients, blood pressure increases are age-dependent and are determined with salivary melatonin levels
References
Andrassy, K. M. (2013). Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease’. Kidney international, 84(3), 622-623. doi: 10.1038/ki.2013.243.
Baker, J., & Kimpinski, K. (2018). Role of melatonin in blood pressure regulation: An adjunct anti‐hypertensive agent. Clinical and Experimental Pharmacology and Physiology, 45(8), 755-766. doi: 10.1111/1440-1681.12942.
Carranza-Madrigal, J., Cervantes-Alfaro, J. M., & López-Correa, S. M. (2015). Effect of the melatonin on morning blood pressure surge and norepinephrine endovenous infusion in healthy volunteers. International Journal of Clinical Medicine, 6(07), 458. doi: 10.4236/ijcm.2015.67060
Cipolla-Neto, J., & Amaral, F. G. D. (2018). Melatonin as a hormone: new physiological and clinical insights. Endocrine reviews, 39(6), 990-1028. doi: 10.1210/er.2018-00084.
Girouard, H., Chulak, C., Lejossec, M., Lamontagne, D., & de Champlain, J. (2001). Vasorelaxant effects of the chronic treatment with melatonin on mesenteric artery and aorta of spontaneously hypertensive rats. Journal of hypertension, 19(8), 1369-1377. doi:10.1097/00004872-200108000-00004
Hrenak, J., Paulis, L., Repova, K., Aziriova, S., J Nagtegaal, E., J Reiter, R., & Simko, F. (2015). Melatonin and renal protection: novel perspectives from animal experiments and human studies. Current pharmaceutical design, 21(7), 936-949. doi:10.2174/1381612820666140929092929
Petrova, A., Kondratiuk, V., Karpenko, O., Ostashevska, T., & Krasiuk, E. (2020). The effectiveness of melatonin in the complex treatment of hypertension in patients with stage 5 chronic kidney disease. Georgian Medical News, (299), 87-93. PMID: 32242852
Rao, M. V., Qiu, Y., Wang, C., & Bakris, G. (2008). Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. American Journal of Kidney Diseases, 51(4), 30-37. doi: 10.1053/j.ajkd.2007.12.012.
Reiter, R. J., Tan, D. X., Paredes, S. D., & Fuentes-Broto, L. (2010). Beneficial effects of melatonin in cardiovascular disease. Annals of medicine, 42(4), 276-285. doi: 10.3109/07853890903485748.
Sarafidis, P. A., Persu, A., Agarwal, R., Burnier, M., De Leeuw, P., Ferro, C. J., ... & Kanbay, M. (2017). Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). Nephrology Dialysis Transplantation, 32(4), 620-640. doi: 10.1093/ndt/gfw433.
Touitou, Y., Reinberg, A., & Touitou, D. (2017). Association between light at night, melatonin secretion, sleep deprivation, and the internal clock: Health impacts and mechanisms of circadian disruption. Life sciences, 173, 94-106. doi: 10.1016/j.lfs.2017.02.008.
Vidal-Petiot, E., Elbez, Y., Lüscher, T. F., Fox, K. M., & Steg, P. G. (2018). The 2018 ESC-ESH guidelines for the management of arterial hypertension leave clinicians facing a dilemma in half of the patients. European heart journal, 39(45), 4040-4041. doi: 10.1093/eurheartj/ehy495.
Будневский, А. В., Овсянников, Е. С., & Филина, Н. В. (2016). Роль мелатонина в патогенезе сердечно-сосудистых заболеваний. Кардиоваскулярная терапия и профилактика, 15(5), 97-101. https://doi.org/10.15829/1728-8800-2016-5-97-101
Недогода, С. В., Смирнова, В. О., Барыкина, И. Н., Саласюк, А. С., Хрипаева, В. Ю., Палашкин, Р. В., & Попова, Е. А. (2017). Влияние терапии препаратом мелатонина на функцию эндотелия, артериальное давление и сосудистую жесткость у пациентов с метаболическим синдромом и нарушениями сна. Артериальная гипертензия, 23(2):150-159. https://doi.org/10.18705/1607-419X-2017-23-2-150-159
Пальман, А. Д., & Рапопорт, С. И. (2014). Мелатонин и артериальная гипертензия: от понимания патогенеза к терапевтическим возможностям. Клиническая медицина, 92(8): 14-18.
Подзолков В.И., Брагина А.Е. (2018). Хроническая болезнь почек как мультидисциплинарная проблема современной медицины. Терапевтический архив, 6: 121-129.
ISSN 
ISSN 
